Trial Profile
Phase II Study of 2-Chlorodeoxyadenosine (2CDA) Followed by Rituximab in Hairy Cell Leukemia
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 25 May 2023
Price :
$35
*
At a glance
- Drugs Cladribine (Primary) ; Rituximab (Primary)
- Indications Hairy cell leukaemia
- Focus Adverse reactions; Therapeutic Use
- 22 May 2023 Planned End Date changed from 30 Jun 2023 to 30 Jun 2024.
- 22 May 2023 Planned primary completion date changed from 30 Jun 2023 to 30 Jun 2024.
- 07 Oct 2019 Planned End Date changed from 1 Jun 2023 to 30 Jun 2023.